What has Tirzepatide research found about weight reduction, maintenance, body composition and direct comparisons?
Continued study treatment maintained prior weight reduction better than switching to placebo, supporting research into long-term weight management. Another study reported mean weight changes of −20.2% with tirzepatide and −13.7% with semaglutide, with greater reductions in weight and waist circumference in the former group.[1] ↗ [2] ↗
Five original studies related to this page's topic are currently selected. They include different designs, populations or formulations; the number of papers is not a clinical efficacy rating for the product. This page is a use-oriented selection of positive research materials, rather than a systematic review or administration advice. Historical research, combination formulations and specialized models are identified separately.
Comparison of study design and results
Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.
| Literature | Study subjects and design | Observation and discovery | Scope of Explanation |
|---|---|---|---|
| 2026 · PMID 42119587 | Adult obesity; after 60 weeks of open weight loss, 378 people entered a 52-week randomized maintenance phase | Continued treatment was more effective than switching to placebo in maintaining previous weight loss, supporting long-term weight management research. | Selects populations who completed the importation period; there are remedial treatments and different estimated targets. Attached is the correction for PMID42242249; numerical values need to be checked against the corrected original text; does not directly provide individual dose reduction plans. |
| 2025 · PMID 40353578 | SURMOUNT-5; 751 adults with obesity without type 2 diabetes; 72-week randomized open-label controlled trial | Average weight change: Terbipetide −20.2%, Semaglutide −13.7%; the former shows greater weight and waist reduction. | Limited to this trial population, maximum tolerated study dose, and 72-week conditions; common adverse events are gastrointestinal responses. Study drug is not equivalent to the research product on this site. |
| 2025 · PMID 39996356 | SURMOUNT-1 DXA sub-study; 160 people, 72 weeks | The Terebopetide group showed greater reductions in weight and fat mass than placebo; about 75% of weight loss in both groups came from fat mass. | About 25% of weight loss comes from lean body mass and cannot be marketed as fat-only loss without muscle loss; it is a sub-study of the parent trial, not an independent replication. |
| 2025 · PMID 39536238 | SURMOUNT-1; 1,032 people with obesity and prediabetes; 176-week randomized study | The study shows average weight loss across dosage groups of 12.3%–19.7%, placebo 1.3%, supporting long-term weight management. | Limited to obese populations with prediabetes; shares parent trial with DXA paper; common gastrointestinal adverse events should be understood in context of the original text. |
| 2024 · PMID 38078870 | SURMOUNT-4; 670 people randomized for 52 weeks after a 36-week lead-in | Among continued treatment participants, 89.5% maintained at least 80% of induction-phase weight loss, compared to 16.6% of those switched to placebo, supporting weight maintenance studies. | To complete the import phase in a specific population; changes after randomization cannot be confused with changes from week 0; not personal medication advice. |
References
How Can Long-Term Weight Reduction Be Maintained?
Continued treatment was more effective than switching to placebo in maintaining previous weight loss, supporting long-term weight management research.[1] ↗
Adult obesity; after 60 weeks of open weight loss, 378 people entered a 52-week randomized maintenance phase
Selects populations who completed the importation period; there are remedial treatments and different estimated targets. Attached is the correction for PMID42242249; numerical values need to be checked against the corrected original text; does not directly provide individual dose reduction plans.
View the Article Title and Full Citation＋
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
Lancet (London, England) · Volume, issue, year 2026
First published 2026-05-12 · PMID 42119587
DOI 10.1016/S0140-6736(26)00656-2
Attached journal correction:PMID 42242249 ↗; this page does not cite the precise weight loss numbers in the paper that are yet to be verified.
How Did Weight Reduction Compare with Semaglutide?
Average weight change: Terbipetide −20.2%, Semaglutide −13.7%; the former shows greater weight and waist reduction.[2] ↗
SURMOUNT-5; 751 adults with obesity without type 2 diabetes; 72-week randomized open-label controlled trial
Limited to this trial population, maximum tolerated study dose, and 72-week conditions; common adverse events are gastrointestinal responses. Study drug is not equivalent to the research product on this site.
View the Article Title and Full Citation＋
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
The New England Journal of Medicine · Volume, Issue, Year 2025
First published 2025-05-11 · PMID 40353578
DOI 10.1056/NEJMoa2416394
Did Weight Reduction Mainly Come from Fat?
The Terebopetide group showed greater reductions in weight and fat mass than placebo; about 75% of weight loss in both groups came from fat mass.[3] ↗
SURMOUNT-1 DXA sub-study; 160 people, 72 weeks
About 25% of weight loss comes from lean body mass and cannot be marketed as fat-only loss without muscle loss; it is a sub-study of the parent trial, not an independent replication.
View the Article Title and Full Citation＋
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
Diabetes, obesity & metabolism · Volume and Issue Year 2025
First published 2025-02-25 · PMID 39996356
DOI 10.1111/dom.16275
Can Weight Reduction Persist for Three Years?
The study shows average weight loss across dosage groups of 12.3%–19.7%, placebo 1.3%, supporting long-term weight management.[4] ↗
SURMOUNT-1; 1,032 people with obesity and prediabetes; 176-week randomized study
Limited to obese populations with prediabetes; shares parent trial with DXA paper; common gastrointestinal adverse events should be understood in context of the original text.
View the Article Title and Full Citation＋
Tirzepatide for Obesity Treatment and Diabetes Prevention.
The New England Journal of Medicine · Volume, Issue, Year 2025
First published 2024-11-13 · PMID 39536238
DOI 10.1056/NEJMoa2410819
What Does Continued Treatment Mean for Weight-Loss Maintenance?
Among continued treatment participants, 89.5% maintained at least 80% of induction-phase weight loss, compared to 16.6% of those switched to placebo, supporting weight maintenance studies.[5] ↗
SURMOUNT-4; 670 people randomized for 52 weeks after a 36-week lead-in
To complete the import phase in a specific population; changes after randomization cannot be confused with changes from week 0; not personal medication advice.
View the Article Title and Full Citation＋
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
JAMA · Volume/Issue/Year 2024
First published 2024-01-02 · PMID 38078870
DOI 10.1001/jama.2023.24945
Common issues and corresponding evidence
What has Tirzepatide research found about weight reduction, maintenance, body composition and direct comparisons?＋
Continued study treatment maintained prior weight reduction better than switching to placebo, supporting research into long-term weight management. Another study reported mean weight changes of −20.2% with tirzepatide and −13.7% with semaglutide, with greater reductions in weight and waist circumference in the former group.[1] ↗ [2] ↗
Does all the weight lost come from fat?＋
No. In the DXA substudy, approximately 75% of weight loss came from fat mass and approximately 25% from lean mass. Lean mass is not the same as muscle alone, so this cannot be described as 'losing only fat without losing muscle.'[3] ↗
Which study populations do these Tirzepatide findings apply to?＋
Adult obesity; after 60 weeks of open weight loss, 378 people entered a 52-week randomized maintenance phase; SURMOUNT-5; 751 obese adults without type 2 diabetes; 72-week randomized open control; SURMOUNT-1 DXA sub-study; 160 people, 72 weeks. Selecting people who completed the induction phase; remedial treatment and different estimation targets exist. Corrected PMID42242249 attached, values must be verified with the original corrected text; does not directly provide individual reduction plans.[1] ↗ [2] ↗ [3] ↗
Tirzepatide
Return to catalog specifications and batch file verification entry.
